Happy National Intern Day! In recognition of today, we would like to share our Summer 2024 Interns. Trevi is a proud participant in the Greater New Haven Bioscience Collaborative's Life-Science Sprints in Connecticut Internship Program, bringing talented students to Connecticut! #bioscience #connecticut #NewHaven
Trevi Therapeutics, Inc.
Biotechnology Research
New Haven, CT 2,705 followers
Clinical-stage biopharmaceutical company
About us
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.
- Website
-
http://trevitherapeutics.com
External link for Trevi Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New Haven, CT
- Type
- Privately Held
- Founded
- 2011
Locations
-
Primary
195 Church Street
14th Floor
New Haven, CT 06510, US
Employees at Trevi Therapeutics, Inc.
Updates
-
At Trevi, we strive to understand the impact that constant #cough can have on both patients & families. Our team is actively developing an investigational treatment for chronic cough in the hopes of providing relief to patients. Learn more: https://ow.ly/tYrq50St7aW
-
-
Our team is looking forward to driving further conversation around chronic #cough while connecting with global experts and leaders at the Thirteenth London International Cough Symposium 2024. Learn more about our current progress in chronic cough and our recruiting trials: https://ow.ly/3OZF50St74E
-
-
Two abstracts on our ongoing chronic cough trials will be presented at the 13th London International Cough Symposium 2024 this week. We can’t wait to share our trial design and use of the sample size reestimation guidance with the #cough community in the development of Haduvio for chronic cough.
-
-
Our Ph2a post hoc analysis presented at the American Thoracic Society 2024 International Conference supports the significant reduction of chronic #cough Bouts. Learn more about our previous trial results in IPF: https://ow.ly/ICCy50St6IX #clinicaltrials #pulmonaryfibrosis #biotechnology #healthcare
-
-
The Trevi team is Boston bound. Join Trevi’s President and CEO, Jennifer Good, and CFO, Lisa Delfini at Leerink Partners Therapeutics Forum: I&I and Metabolism. We are excited to connect with investors and discuss Trevi Therapeutics development plans in chronic cough. #healthcare #biotechnology #clinicaltrials #chroniccough #cough
-
-
The Trevi team is traveling this summer. We are pleased to announce our attendance of Leerink Partners Therapeutics Forum: I&I and Metabolism, Oppenheimer & Co. Inc.’s Biotech in the Berkshires and Stifel’s 2024 Biotech Summer Summit. In addition, we are thrilled to announce two abstracts were accepted on our ongoing cough trials. Read more: https://lnkd.in/evwkJxNh Connect with us if you are attending any of these events to continue our discussion on the unmet need in chronic cough and our potential to be a first-in-class therapy for IPF patients suffering with chronic cough. #healthcare #cough #clinicaltrials #biotech
-
-
Learn more about our therapeutic focus in chronic #cough and the current unmet need in #IPF and #RCC, please visit https://ow.ly/M2AM50RuMgX. We are committed to advancing our research for patients in need. Follow our page to see our progress. #clinicaltrials #research #idiopathicpulmonaryfibrosis #RCC
-
-
Reminder: If you are attending Oppenheimer & Co. Inc.’s 2024 Montauk Life Sciences Summit this week, be sure to connect with our CFO Lisa Delfini.
-